Latent Raises $80 Million Series A to Scale AI-Powered Medication…

Team S · 2026-04-08T15:27:17.000Z

San Francisco-based clinical AI startup Latent has raised $80 million in a Series A funding round, marking a major step forward in transforming how patients access life-saving medications through intelligent automation. The round was co-led by Spark Capital and Transformation Capital, with participation from General Catalyst, McKesson Ventures, Conviction, and Y Combinator, reflecting strong investor confidence in the growing role of AI in healthcare infrastructure. Latent is building a clinical AI platform that automates complex medication access workflows, helping healthcare providers move patients from diagnosis to treatment faster and more efficiently. Its core product, a Clinical Reasoning Engine, integrates patient data, payer requirements, and pharmacy operations to eliminate delays caused by manual processes. The company’s technology addresses a critical bottleneck in healthcare, where administrative burdens and prior authorization processes often delay treatment. By leveraging AI to interpret clinical data and manage approvals, Latent significantly reduces inefficiencies and improves patient outcomes. Currently, the platform is used by over 45 leading health systems and supports millions of patients annually, demonstrating strong adoption across the US healthcare ecosystem. The newly raised capital will be used to expand its presence across health systems, deepen integrations with hospitals, payers, and pharmacies, and scale its AI-driven platform, as the company continues to build a unified infrastructure connecting key stakeholders in the healthcare value chain. This funding highlights a broader trend of rising investment in AI-driven healthcare solutions, where automation and data intelligence are becoming essential to improving efficiency, reducing delays, and enabling better patient care at scale.

Member Login Get Access

Latent Raises $80 Million Series A to Scale AI-Powered Medication… | Newnex